Abstracts tagged "Immunodeficiency"

Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium
Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Mei-Sing Ong¹, Deborah Rothman ² and Marc Natter ³, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Massachusetts General Hospital, Springfield, ³Boston Children's Hospital, Boston
Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
Abstract Number: 2460 • 2018 ACR/ARHP Annual Meeting
Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients
Yoshihiko Ikeno¹, Youkou Kobayashi², Ikuo Akutsu³, Hirokuni Hirata⁴, Masafumi Arima⁵ and Kazuhiro Kurasawa⁶, ¹Rheumatology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ²Hematology, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ³Respiratory and allergy, Japanese Red Cross Nasu Hospital, Tochigi, Japan, ⁴Respiratory and allergy, Dokkyo Medical University Saitama Medical center, Saitama, Japan, ⁵Rheumatology, Dokkyo Medical University, mibu-gun, Tochigi, Japan, ⁶Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan
Background/Purpose: Methotrexate-associated lymphoproliferative disorders (MTX-LPDs) was first reported in 1991. The symptom is known to spontaneously regress after suspending the use of MTX, suggesting its…
Abstract Number: 2838 • 2018 ACR/ARHP Annual Meeting
Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database
Kevin Byram¹, Leonard H. Calabrese² and James Fernandez¹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Vasculitis has been reported in patients with various forms of primary immunodeficiency (PID) in case reports in the literature. The goal of this study…
Abstract Number: 1538 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder
Takuma Tsuzuki Wada¹, Yuji Akiyama¹ and Toshihide Mimura², ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Recently, methotrexate (MTX) has been considered as the anchor drug in the treatment of rheumatoid arthritis (RA). However, it has been reported that MTX…
Abstract Number: 657 • 2012 ACR/ARHP Annual Meeting
Serial Screening Shows That 28% of Systemic Lupus Erythematosus Adult Patients Carry an Underlying Primary Immunodeficiency
Sandro F. Perazzio¹, Reinaldo Salomao², Neusa P. Silva³, Magda Carneiro-Sampaio⁴ and Luis Eduardo C. Andrade⁵, ¹Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Infectology, Federal University of Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Pediatrics, Instituto da Criança da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, ⁵Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil
Background/Purpose: Systemic Lupus Erythematosus (SLE) is known to be associated with deficiency of C1q, C4, and C2. There is high frequency of discoid lesions (2.7%)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].